Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors Lin YuXi YangLiangpeng Ge PRECLINICAL STUDIES 19 November 2020 Pages: 615 - 626
Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells Yafei ChuZheng XiaoYi Li PRECLINICAL STUDIES 19 November 2020 Pages: 627 - 635
4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer Blake A. JacobsonZeeshan AhmadRobert A. Kratzke PRECLINICAL STUDIES 23 November 2020 Pages: 636 - 643
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma Irene Dell’AnnoSarah A. MartinStefano Landi PRECLINICAL STUDIES Open access 09 December 2020 Pages: 644 - 657
Simvastatin treatment varies the radiation response of human breast cells in 2D or 3D culture Katrin MandaDajana JuerßGuido Hildebrandt PRECLINICAL STUDIES Open access 11 December 2020 Pages: 658 - 669
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma Mohamed E. M. SaeedOnat KadiogluThomas Efferth PRECLINICAL STUDIES Open access 12 December 2020 Pages: 670 - 685
BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells Qian LiLiuqian WangAnchun Deng PRECLINICAL STUDIES 02 January 2021 Pages: 686 - 696
Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models Fariba ShiraviMehdi MohammadiFazel Shokri PRECLINICAL STUDIES 03 January 2021 Pages: 697 - 704
Identification of chemoresistance-associated microRNAs and hub genes in breast cancer using bioinformatics analysis Ming WuYujie ZhaoBo Chen PRECLINICAL STUDIES 04 January 2021 Pages: 705 - 712
The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasion Yuting HeJianming ZhouQinsi Wan PRECLINICAL STUDIES 06 January 2021 Pages: 713 - 723
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways Akihiro MiuraHiroshi SootomeHiroshi Hirai PRECLINICAL STUDIES 06 January 2021 Pages: 724 - 735
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia Renata Scopim-RibeiroJoão Agostinho Machado-NetoFabiola Traina PRECLINICAL STUDIES 06 January 2021 Pages: 736 - 746
A rat toxicological study of intra-arterial injection of Tirapazamine, a hypoxia-activating Cancer therapeutic agent, followed by hepatic artery ligation Chang-Hsien LiuShih-Ming KuoYu-Juei Hsu PRECLINICAL STUDIES 11 January 2021 Pages: 747 - 755
Toxicokinetics of the tumour cell mitochondrial toxin, PENAO, in rodents Philip J. Hogg PRECLINICAL STUDIES 19 January 2021 Pages: 756 - 763
Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer Ying WangZhigang HuPengxin Zhao PHASE I STUDIES 27 November 2020 Pages: 764 - 774
The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathway Yujian DaiHuiming ZhengWeize Hu PHASE I STUDIES 07 January 2021 Pages: 775 - 784
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers J. WuD. LiuM. E. Lacouture PHASE I STUDIES 03 January 2021 Pages: 785 - 795
Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers Lei LiYu-xia XiangJie Huang PHASE I STUDIES 09 January 2021 Pages: 796 - 802
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors Georgina Meneses-LorenteDarren BentleyAlex Phipps PHASE I STUDIES Open access 18 January 2021 Pages: 803 - 811
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879 David I. QuinnDenice D. Tsao-WeiEdward Newman PHASE II STUDIES 06 January 2021 Pages: 812 - 820
Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma Cara KenneyTricia KunstUdo Rudloff SHORT REPORT Open access 06 January 2021 Pages: 821 - 828
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial Jeffrey A. HowAmir JazaeriAung Naing SHORT REPORT 07 January 2021 Pages: 829 - 835
Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study Liu-Fang YeChao RenDe-Shen Wang SHORT REPORT 07 January 2021 Pages: 836 - 845
Effectiveness of cetuximab as preemptive postsurgical therapy for oral squamous cell carcinoma patients with major risk: a single‐center retrospective cohort study Chonji FukumotoYuta SawataniHitoshi Kawamata Short Report Open access 15 January 2021 Pages: 846 - 852
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study Takeya SugimotoDaichi FujimotoNobuyuki Yamamoto PHASE III STUDIES 06 January 2021 Pages: 853 - 859
Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis Han LiJinsheng XuJingjing Jin Review Open access 06 January 2021 Pages: 860 - 870
Gut microbiota homeostasis restoration may become a novel therapy for breast cancer Zhi-Peng FengHong-Yi XinHong-Wu Xin Review 17 January 2021 Pages: 871 - 878
Advances in anti-BRAF therapies for lung cancer Giandomenico RovielloAlberto D’AngeloNavid Sobhani REVIEW Open access 21 January 2021 Pages: 879 - 890
Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors Zongqiong SunSheng WangYonggang Li CLINICAL TRIAL METHODOLOGY 11 January 2021 Pages: 891 - 898
Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer Hiroto InoueAkira OnoToshiaki Takahashi Correction 26 June 2020 Pages: 899 - 899